Regulatory News:
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP & OTC
US: EYRYY), the French biopharmaceutical company that develops
innovative ‘tumor starvation’ treatments for acute leukemia and other
oncology indications with unmet medical needs, announces its financial
calendar for 2015.
|
February 10, 2015:
|
|
|
Publication of full year 2014 revenues (after market)
|
|
March 30, 2015:
|
|
|
Publication of 2014 annual results (after market)
|
|
May 5, 2015:
|
|
|
Publication of Q1 2015 revenues (after market)
|
|
June 23, 2015:
|
|
|
Annual shareholders’ meeting
|
|
July 8, 2015:
|
|
|
Publication of Q2 2015 revenues (after market)
|
|
September 28, 2015:
|
|
|
Publication of H1 2015 results (after market)
|
|
November 3, 2015:
|
|
|
Publication of Q3 2015 revenues (after market)
|
Beyond these periodicals, investors are invited to consult the website
of the company (www.erytech.com)
where information is regularly updated. All corporate and financial
information on the company is available on the company’s website, in the
Investors’ section.
About ERYTECH: www.erytech.com
Created in Lyon in 2004, ERYTECH is a French biopharmaceutical company
providing new prospects for cancer patients, particularly those with
acute leukemia and selected solid tumors.
By encapsulating the asparaginase enzyme in red blood cells, ERYTECH has
developed ERY-ASP/GRASPA® , an original treatment that targets cancer
cells through “tumor starvation” while significantly reducing the side
effects for patients. ERY-ASP/GRASPA® has recently announced positive
Phase III data in Acute Lymphoblastic Leukemia (ALL) and is in Phase IIb
clinical trial in Acute Myeloid Leukemia (AML) in Europe. The product is
also in Phase I/II clinical development in ALL in the USA.
Every year about 50,000 patients are diagnosed with Acute Lymphoblastic
Leukemia (ALL) or Acute Myeloid Leukemia (AML), the two forms of acute
leukemia. Today, for about 80% of these patients, mainly adults and
relapsing patients, current forms of asparaginase cannot be used due to
their toxicity. With a presumed improved safety profile, ERY-ASP/GRASPA®
is being developed to allow all leukemia patients to be treated, even
the most fragile ones, representing a market opportunity of more than
EUR 1 billion.
The company is also developing other indications in solid tumors and
certain orphan indications outside oncology. A Phase II study in
pancreas cancer is ongoing and the company is exploring other solid
tumor indications for ERY-ASP.
ERYTECH has obtained orphan drug designations for ERY-ASP/GRASPA® in
ALL, AML and pancreas cancer, both in Europe and the USA, and has its
own GMP-approved and operational manufacturing site in Lyon (France),
and a site for clinical production in Philadelphia (USA).
The company has concluded licensing and distribution partnership
agreements for ALL and AML in Europe with Orphan Europe (Recordati
Group), and for ALL with TEVA in Israel.
ERYTECH is listed on Euronext regulated market in Paris (ISIN code:
FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC
Pharma & Bio, CAC Mid&Small, CAC All Tradable, EnterNext PEA-PME 150 and
Next Biotech indexes. ERYTECH is also listed in the US under an ADR
level 1 program (OTC, ticker EYRYY).
Copyright Business Wire 2015